Johnson & Johnson

NYSE:JNJ

Drug Manufacturers - General

Healthcare
$272.70 -1.96%

-$4.59 today

Market cap
$656.47B
Beta
0.26
P/E (TTM)
26.7
EPS (TTM)
$8.60
Dividend yield
2.28%
52W Low $149.04High $251.71

Volume 7.93M

Average 7.71M

JNJ Total Non-current Liabilities

All obligations due after more than one year.

Johnson & JohnsonNYSE: JNJ

Total Non-current Liabilities · Q3 FY2026 · quarter ended Sep 2026

Total non-current liabilities falls 3.6% from a year ago

Total non-current liabilities stood at $60.44B at the end of Q3 FY2026, down 3.6% from a year earlier and down 1.2% from the prior quarter. Over 3 fiscal years it compounded at +5.1% a year.

Context

  • Total non-current liabilities amounted to 30.6% of total assets at the end of Q3 FY2026, down 1.9 pp from a year earlier.
  • Total non-current liabilities increased in 2 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether total non-current liabilities keeps falling in the next quarterly balance sheet after a -3.6% change from a year earlier.

Sources:Balance SheetText generated from reported figures; not investment advice.

Latest quarterSep 2026
$60.44B-1.2% QoQ
Last fiscal yearDec 2025
$63.54B+9.0% YoY
Year agoSep 2025
$62.67B-3.6% since
Total Non-current Liabilities past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-3.6%——
1 year+9.0%——
3-year CAGR+5.1%——
5-year CAGR——
10-year CAGR——

Total Non-current Liabilities history

USD · from the balance sheet

Latest · FY2025
63.54B USD
Year-over-year change
+9.0%
4-year CAGR
+0.3%

Total Non-current Liabilities vs competitors

How JNJ compares with its peers on the latest reported figures

  • Peers report in different currencies, so total non-current liabilities is compared through growth and share of total assets rather than absolute size.
  • Its year-over-year change of -3.6% is the 9th highest of 11, against a peer median of +5.6%.
  • Total non-current liabilities amounts to 30.6% of total assets for JNJ, versus a peer median of 43.8%.
JNJ Competitors
Total Non-current Liabilities for JNJ and competitors
Company Period Latest balance YoY 3-year CAGR% of assets
ABBVAbbVie Inc.Jun 2026$99.36B USD+1.9%+0.7%73.5%
PFEPfizer Inc.Jun 2026$82.99B USD+4.6%+12.6%41.3%
JNJJohnson & JohnsonSep 2026$60.44B USD-3.6%+5.1%30.6%
MRKMerck & Co., Inc.Jun 2026$60.09B USD+41.6%+12.9%46.3%
AMGNAmgen Inc.Jun 2026$58.45B USD-2.6%+7.2%61.1%
NVSNovartis AGJun 2026$48.34B USD+57.8%+12.4%39.6%
BMYBristol-Myers Squibb CompanyJun 2026$46.66B USD-6.0%+3.2%53.2%
AZNAstraZeneca PLCSep 2026$36.78B USD+6.8%+1.6%30.7%
SNYSanofiJun 2026€27.56B EUR+7.6%-1.0%21.4%
GILDGilead Sciences, Inc.Jun 2026$26.6B USD+6.6%-7.2%53.9%
GSKGSK plcJun 2026£22.89B GBP-31.9%-4.6%37.3%
Peer median (excluding JNJ) —+5.6%+2.4%43.8%

Competitors are the stored peer set for JNJ. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Balance Sheet

USD
Metric
FY2021
Jan 2022
FY2022
Jan 2023
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Cash & Equivalents14.49B12.89B21.86B24.11B19.71B
Short-term Investments17.12B9.39B1.07B417M393M
Net Receivables18.98B16.92B14.87B18.93B17.18B
Inventory10.39B10.27B11.18B12.44B14.19B
Other Current Assets(3.7B)5.83B004.15B
Total Current Assets60.98B55.29B53.5B55.89B55.62B
Property, Plant & Equipment (Net)18.96B17.98B19.9B20.52B23.17B
Goodwill35.25B36.05B36.56B44.2B48.77B
Intangible Assets46.39B38.49B34.18B37.62B50.4B
Long-term Investments00000
Tax Assets10.22B8.95B9.28B10.46B6.87B
Other Non-current Assets10.22B30.62B14.15B11.41B14.37B
Total Non-current Assets121.04B132.08B114.06B124.21B143.59B
Total Assets182.02B187.38B167.56B180.1B199.21B
Account Payables11.06B9.89B9.63B10.31B11.99B
Short-term Debt3.77B12.76B3.45B5.98B8.5B
Tax Payables1.11B2.22B2.99B3.77B0
Deferred Revenue00000
Other Current Liabilities3.59B6.64B3.99B4.13B4.53B
Total Current Liabilities45.23B55.8B46.28B50.32B54.13B
Long-term Debt29.99B26.89B25.88B30.65B39.44B
Deferred Tax Liabilities7.49B3.99B3.19B2.45B6.79B
Deferred Revenue (Non-current)00000
Other Non-current Liabilities25.3B23.9B23.43B25.19B17.31B
Total Non-current Liabilities62.77B54.77B52.5B58.29B63.54B
Total Liabilities108B110.57B98.78B108.61B117.67B
Common Stock3.12B3.12B3.12B3.12B3.12B
Retained Earnings123.06B128.35B153.84B155.79B168.98B
Accumulated OCI(13.06B)(12.97B)(12.53B)(11.74B)(14.93B)
Other Stockholders Equity(123.06B)(128.35B)(153.84B)00
Minority Interest00000
Total Equity74.02B76.8B68.77B71.49B81.54B
Total Debt33.75B39.64B29.33B36.63B47.93B
Net Debt19.26B26.75B7.47B12.53B28.22B

Johnson & Johnson

NYSE:JNJ

Intrinsic Alpha fair value

Locked

Current Price

$272.70

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.